国产帕罗西汀与阿米替林门诊治疗抑郁症患者的对照研究

目的比较国产帕罗西汀与阿米替林治疗门诊抑郁症的临床疗效和不良反应。方法对60例抑郁症患者随机分为两组,分别给予国产帕罗西汀和阿米替林治疗6周。采用汉密尔顿抑郁量表(HAMD)、汉密顿焦虑量表(HAMA)、临床疗效总评量表(CGI)评定疗效,用不良反应量表(TESS)评定不良反应。结果国产帕罗西汀组有效率为83.33%,与阿米替林组比较差异无显著性;但国产帕罗西汀的起效快,不良反应少。结论国产帕罗西汀治疗是一种安全有效的抗抑郁剂。     

西酞普兰合并低剂量阿米替林与帕罗西汀治疗抑郁症的疗效观察

目的探讨西酞普兰合并低剂量阿米替林与帕罗西汀治疗抑郁症的疗效价值和安全性。方法对2009年1月-2009年10月我院门诊及住院抑郁症患者112例,随机分为西酞普兰合并低剂量阿米替林组和帕罗西汀组各56例,疗程6周,采用汉密顿抑郁量表（HAMD）和不良反应量表（TESS）在治疗前、后1、2、4、6周末评定药物疗效和不良反应。结果西酞普兰合并低剂量阿米替林和帕罗西汀两组治疗1～2周前后HAMD评分差异有显著性（P〈0．05）,治疗4—6周,两组差异无显著性（P〉0．05）,西酞普兰合并低剂量阿米替林组不良反应总发生率为26．79％,帕罗西汀则为46．43％,两组差异有显著性（P〈0．05）。结论西酞普兰合并低剂量阿米替林与帕罗西汀治疗抑郁症均有效,不良反应较轻,但西酞普兰合并低剂量阿米替林更安全,服用方便,不良反应更小,可作为治疗抑郁症的首选联合药物。     

帕罗西汀与阿米替林治疗抑郁症的疗效对比分析

目的帕罗西汀对抑郁症疗效好,比阿米替林副反应低,更为安全可靠。方法对98例门诊及住院的抑郁症患者随机分为两组,分别在治疗前和治疗后第1、2、4及6周末进行相关师表测定,并进行对照分析。结果疗效比较：帕罗西汀组显效率为78.6%,阿米替林组为75.8%。不良反应比较：帕罗西汀组不良反应12例（24%）,阿米替林组出现不良反应21例（43%）。结论帕罗西汀与阿米替林对的抑郁症均有显著疗效,且疗效相当。但不良反应方面,帕罗西汀较阿米替林副反应轻。由此可见,帕罗西汀可以作为治疗抑郁症的道选药。     

帕罗西汀与阿米替林治疗抑郁症比较

目的 :比较帕罗西汀和阿米替林治疗抑郁症疗效和不良反应。方法 :选择符合条件的住院或门诊病人 6 0例 ,分成 2组。帕罗西汀组 30例 [男性14例 ,女性 16例 ,年龄 (42±s 15 )a],阿米替林组30例 [男性 14例 ,女性 16例 ,年龄 (43± 14 )a],分别口服帕罗西汀 2 0mg·d- 1和阿米替林 5 0mg·d- 1,依病情可调整至 4 0mg·d- 1和 2 5 0mg·d- 1。用HAMD ,TESS进行评定。结果 :2组治疗抑郁症时起效时间、疗效相当 ,帕罗西汀组显效率 80 % ,阿米替林组显效率 73% (P >0 .0 5 ) ,帕罗西汀组的不良反应轻微 ,仅少数病人失眠较明显。结论 :帕罗西汀治疗抑郁症与阿米替林疗效相似 ,但不良反应轻微 ,使用方便。     

麦普替林与帕罗西汀治疗抑郁症对照研究

目的研究麦普替林与帕罗西汀对抑郁症的疗效及副反应。方法60例抑郁症患者随机分为麦普替林组与帕罗西汀组治疗8周。治疗前后分别用Hamilton抑郁量表(HAMA)和副反应量表(TESS)测定疗效和安全性。结果麦普替林和帕罗西汀对抑郁症均有良好疗效，差异无显著性。不良反应均较轻微。结论麦普替林与帕罗西汀对抑郁症疗效相仿。     

帕罗西汀与阿米替林治疗抑郁症对照研究的Meta分析

目的：进一步认识帕罗西汀与阿米替林治疗抑郁症的疗效和不良反应差异。方法：收集国内医药杂志上公开发表的6篇帕罗西汀与阿米替林对照治疗抑郁症研究的文章，作Meta分析。结果：帕罗西汀自身对照比较的治疗效应极大，与阿米替林组间比较没有显著性，差异效应偏小；帕罗西汀组的心动过速、锥外反应、便秘、口干和视力模糊，显著少于阿米替林组，差异有显著性，差异强度偏大。结论：帕罗西汀与阿米替林6周的疗效无差异，但不良反应显著性不同。     

万拉法辛与阿米替林治疗抑郁症的对照研究

目的比较文拉法辛与阿米替林治疗抑郁症的疗效及不良反应。方法将60例符合CCMD-3抑郁症的诊断标准的患者随机平分为两组,分别给予文拉法辛与阿米替林治疗6周。采用汉密尔顿抑郁量表（HAMD）、副反应量表（TESS）评定疗效及不良反应。结果文拉法辛组显效率为80．00％,阿米替林组显效率为76．67％,2组疗效差异无显著意义（P〉0．05）,文拉法辛组起效快,文拉法辛组不良反应较阿米替林组小。结论文拉法辛治疗抑郁症疗效良好,起效快,不良反应轻。     

阿采替林合用活血舒郁汤治疗抑郁症临床观察（附70例分析）

目的探讨阿米替林合用活血舒郁汤治疗抑郁症的临床疗效。方法将70例抑郁症患者随机分为治疗组和对照组，分别给予阿米替林合用活血舒郁汤和单用阿米替林治疗，观察时间8周，以汉密顿抑郁量表（HAMD）评定疗效。结果两组患者在治疗前后HAMD评分差异均具有统计学意义（P〈O．01）；合用活血舒郁汤组的患者在治愈率方面较单用阿米替林组高，差异具有统计学意义（P〈0．05）。结论阿米替林合用活血舒郁汤治疗抑郁症的疗效优于单用阿米替林，具有确切的增效作用。     

阿米替林合用活血舒郁汤治疗抑郁症临床观察(附70例分析)

目的探讨阿米替林合用活血舒郁汤治疗抑郁症的临床疗效。方法将70例抑郁症患者随机分为治疗组和对照组,分别给予阿米替林合用活血舒郁汤和单用阿米替林治疗,观察时间8周,以汉密顿抑郁量表(HAMD)评定疗效。结果两组患者在治疗前后HAMD评分差异均具有统计学意义(P<0.01);合用活血舒郁汤组的患者在治愈率方面较单用阿米替林组高,差异具有统计学意义(P<0.05)。结论阿米替林合用活血舒郁汤治疗抑郁症的疗效优于单用阿米替林,具有确切的增效作用。     

帕罗西汀与阿米替林治疗躯体化障碍对照研究

目的比较帕罗西汀与阿米替林治疗躯体化障碍的疗效和不良反应。方法81例躯体化障碍病人随机分成2组,分别用帕罗西汀与阿米替林治疗8wk。用SCL-90中的躯体化,抑郁和焦虑3个因子总分评定症状变化,用不同减分率评定疗效。用不良反应量表TESS评定药物不良反应。结果帕罗西汀组痊愈率为61.90%,总有效率为90.48%;阿米替林的痊愈率为43.59%,总有效率为71.79%,2组疗效比较差异有显著意义(P<0.05)。2组TESS测评,各时点组间比较,差异均有显著意义(P<0.05或P<0.01)。结论帕罗西汀治疗躯体化障碍疗效确切,不良反应较小。     

噻奈普汀与阿米替林治疗老年抑郁症的对照研究

目的:探讨噻奈普汀治疗老年抑郁症的疗效及安全性。方法:对62例老年抑郁症病人随机分为两组,分别给予噻奈普汀与阿米替林治疗6周。采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)评定疗效,用不良反应量表(TESS)评定不良反应。结果:噻奈普汀与阿米替林疗效相似,没有严重不良反应。结论:噻奈普汀治疗老年抑郁症疗效好,不良反应轻,患者药物依从性好。     

Viloxazine and amitriptyline in endogenous depression

In a double-blind clinical trial carried out on 20 outpatients with the diagnosis of endogenous depression, amitriptyline (75–225 mg) was found to be somewhat faster in its therapeutic effects on depression than viloxazine (150–450 mg), whereas viloxazine was somewhat faster in its therapeutic effect on anxiety. Cardiovascular adverse effects were only encountered with amitriptyline, whereas gastrointestinal side effects were present with viloxazine.     

A placebo-controlled multicenter trial of Limbitrol versus its components (amitriptyline and chlordiazepoxide) in the symptomatic treatment of depressive illness

In a multicenter, placebo-controlled, clinical trial, the efficacy of Limbitrol was compared with that of its components, amitriptyline and chlordiazepoxide. All patients had a diagnosis of primary depression. Data from 279 patients were evaluated using the Hamilton depression scale, the Beck depression inventory, and physician and patient global change measures.Statistically significant differences favoring Limbitrol occurred after 1 week of treatment, and a trend in favor of Limbitrol continued throughout the remaining 3 weeks. In most efficacy comparisons, the combination was as good as, or better than, amitriptyline alone. It was superior to chlordiazepoxide alone after 2 and 4 weeks of treatment. Each component produced an independent contribution to the total therapeutic effect: the chlordiazepoxide effect was more prominent in the first 2 weeks and the amitriptyline effect in the latter 2 weeks. A trend favoring amitriptyline over chlordiazepoxide was evident by week 4.The overall incidence of side effects was comparable in both Limbitrol- and amitriptyline-treated groups. Limbitrol-treated patients exhibited more sedation, but significantly fewer Limbitrol patients discontinued treatment prematurely because of side effects.     

西酞普兰与阿米替林治疗抑郁症的临床对照研究

目的:评价西酞普兰与阿米替林治疗抑郁症的临床疗效和安全性。方法:将55例符合CCMD-3抑郁症诊断标准的抑郁症患者随机分为两组,分别给予西酞普兰和阿米替林治疗,于治疗前和治疗后1、2、4、6周末分别采用汉密顿抑郁量表(HAMD)、临床疗效总体评定量表(CGI-SI)及不良反应量表(TESS)评定。结果:西酞普兰与阿米替林总体疗效相似,两组比较差异无显著性(P>0.05)。西酞普兰组治疗1周开始起效,两组治疗前后比较HAMD量表差异均有极显著性(P<0.01),治疗2、4、6周末两组之间比较差异无显著性(P>0.05),西酞普兰组的不良反应少于阿米替林组。结论:西酞普兰是一种安全有效的新一代抗抑郁药物。     

西酞普兰治疗阿尔茨海默氏病抑郁症状的对照研究

目的 比较西酞普兰与阿米替林治疗阿尔茨海默氏病抑郁症状的疗效和安全性。方法 将63例住院患者随机分为两组，分别给予西酞普兰（治疗组）和阿米替林（对照组）治疗，观察8周，于治疗前和治疗后1，2，4，8周末分别采用汉密尔顿抑郁量表（HAMD）和副反应量表（TESS）评定疗效和不良反应。结果 两组疗效相近，但治疗组起效较快，不良反应少而轻微。结论 西酞普兰治疗阿尔茨海默氏病抑郁症状安全有效，值得临床推广应用。     

Amitriptyline and hydroxylated metabolite plasma levels in depressed outpatients

As part of a double-blind clinical trial comparing phenelzine and amitriptyline in outpatients with predominantly major depressive disorder, plasma tricyclic antidepressant drug concentrations were measured in 83 amitriptyline-treated patients. In 29 of these patients, hydroxymetabolites were also assayed. Patients were treated for 6 weeks at a fixed dose of 150 mg/day of amitriptyline after the first 5 days. Therapeutic outcome was assessed with a structured depression interview schedule, the Symptom Checklist-90, a side effects checklist, and a global improvement scale. Steady state plasma levels of 10-hydroxynortriptyline were in the same range as amitriptyline or nortriptyline concentrations. Clinical response did not relate significantly to plasma levels of either the parent drug, its metabolites, or the sum of all four pharmacologically active substances. Minimum threshold tricyclic antidepressant levels for therapeutic effect were not found. Assay of its active hydroxymetabolites does not appear to improve the clinical utility of routine amitriptyline level monitoring in patients with major depression in an outpatient setting.     

Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline

Summary Plasma levels of amitriptyline and nortriptyline were measured twice weekly in 62 patients treated for three weeks with i.m. amitriptyline 120 mg/day. In half the patients the ratio of amitriptyline to nortriptyline was under 1 and in the other half it was greater than 1. 30 of these 62 patients were clinically monitored with the Hamilton Rating Scale and the side effects of the drug were recorded. There was no correlation between plasma level of the drug and its side effects, but there was a statistically significant curvilinear correlation between the plasma levels of amitriptyline plus nortriptyline and nortriptyline alone, and the clinical effect. The practical value of this type of investigation was demonstrated by showing that patients whose drug plasma level was not in the therapeutic range, were clinically improved after adjustment of the dose. The plasma level of amitriptyline plus nortriptyline must lie between 60 to 220 ng/ml, and that of nortriptyline between 60 to 140 ng/ml, to obtain the best clinical effect. Associated treatments, age, weight and sex of patients, and the type of depression did not appear significantly to affect the plasma level of the drug.     

西酞普兰和阿米替林治疗老年抑郁症临床研究

目的 探讨西酞普兰与阿米替林治疗老年抑郁症的疗效及副反应。方法 将72例符合CCMD-3诊断标准的老年抑郁症患者采用随机分组的对照方法，分为西酞普兰组和阿米替林组治疗8周，采用四级临床疗效及HAMD(汉密尔顿抑郁量表)、HAMA(汉密尔顿焦虑量表)和TESS(副反应量表)评定疗效和不良反应。结果 西酞普兰与阿米替林对老年抑郁症的疗效相似，西酞普兰副反应较阿米替林少而轻。结论 西酞普兰是一个既有效又安全的新型抗抑郁药，适合对老年抑郁症的治疗，患者有较好的耐受性。     

帕罗西汀与阿米替林治疗老年抑郁症对照研究

目的：探索对老年抑郁症较理想的治疗药物。方法：采用帕罗西汀与阿米替林对38例老年抑郁症分成两组，每组19例，进行为期6周的双盲对照治疗。结果：帕罗西汀和阿米替林对老年抑郁症疗效相似，但起效帕罗西汀较快，不良作用少而轻微。结论：帕罗西汀是值得推荐的治疗老年抑郁症较理想的药物。     

博乐欣与阿米替林治疗门诊抑郁症患者对照研究

目的比较博乐欣（文拉法辛）与阿米替林治疗门诊抑郁症的临床疗效和不良反应。方法对63例抑郁症患者随机分为两组,分别给予博乐欣和阿米替林治疗8周。采用汉密尔顿抑郁量表（HAMD）、药物不良反应量表（TESS）进行评临床疗效评定不良反应。结果博乐欣与阿米替林嗪显效率差异有显著性,博乐欣组显效快,不良反应少。结论博乐欣是一种安全有效的抗抑郁剂。